GMP IPO Watch
SBI HEALTHCARE OPPORTUNITIES FUND
Direct Plan · IDCW · SBI Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +3.03% | +2.62% | 120 of 255 |
| 1M | +1.13% | +0.77% | 114 of 255 |
| 3M | -0.74% | -4.63% | 37 of 252 |
| 6M | +16.61% | +2.44% | 11 of 251 |
| YTD | +22.07% | +0.02% | 8 of 255 |
| 1Y | +17.68% | -0.51% | 12 of 232 |
| 2Y | +10.74% | +1.57% | 17 of 187 |
| 3Y | +24.49% | +11.99% | 6 of 142 |
| 5Y | +19.13% | +9.56% | 6 of 102 |
| 7Y | +24.69% | +14.11% | 2 of 84 |
| 10Y | +13.08% | +11.42% | 36 of 68 |
| INCEPTION | +16.48% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +4.44% | +46.08% | -26.08% | 67% | 27% |
| 6M | +9.02% | +69.25% | -29.39% | 69% | 28% |
| 1Y | +19.04% | +91.73% | -28.22% | 70% | 30% |
| 2Y | +17.14% | +59.95% | -18.35% | 75% | 33% |
| 3Y | +14.89% | +36.30% | -13.94% | 80% | 35% |
| 5Y | +12.66% | +33.30% | -7.46% | 89% | 39% |
| 7Y | +13.24% | +26.66% | +3.09% | 100% | 44% |
| 10Y | +12.79% | +15.56% | +9.18% | 100% | 45% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity93.66%
- Debt0.05%
- Cash6.29%
- Other0.00%
Market Cap Split
- Large Cap32.32%
- Mid Cap25.69%
- Small Cap37.51%
- Others4.48%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 49.14 | 41.75 |
| P/B | 6.82 | 6.19 |
| Price / Sales | 7.51 | 5.96 |
| Price / Cash Flow | 35.12 | 30.98 |
| Dividend Yield (%) | 0.39 | 0.61 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 11.14% | -1.19% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 7.91% | -0.26% |
| TREPS | Reverse Repo / TREPS | 6.42% | — |
| Acutaas Chemicals | Pharmaceuticals & Biotechnology | 5.03% | +0.12% |
| Apollo Hospitals | Equity | 4.45% | -0.46% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 4.42% | -0.30% |
| Cipla | Pharmaceuticals & Biotechnology | 4.40% | -0.27% |
| Laurus Labs | Pharmaceuticals & Biotechnology | 4.05% | +0.09% |
| Max Healthcare Institute | Equity | 3.80% | -0.51% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 3.42% | -0.48% |
| Aster DM Quality Care | Equity | 3.21% | -0.31% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 2.96% | -0.03% |
| Sudeep Pharma | Chemicals & Petrochemicals | 2.79% | -0.05% |
| Anthem Biosciences | Pharmaceuticals & Biotechnology | 2.75% | -0.15% |
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 2.60% | +0.08% |
View all 38 holdings
| Corona Remedies | Pharmaceuticals & Biotechnology | 2.43% | — |
| Biocon | Pharmaceuticals & Biotechnology | 2.37% | -0.30% |
| Fortis Healthcare | Equity | 2.36% | -0.46% |
| Concord Biotech | Pharmaceuticals & Biotechnology | 2.25% | -0.15% |
| Aether Industries | Chemicals & Petrochemicals | 2.17% | -0.16% |
| Jupiter Life Line Hospital | Equity | 2.16% | -0.39% |
| Poly Medicure | Equity | 1.82% | -0.12% |
| Ajanta Pharma | Pharmaceuticals & Biotechnology | 1.79% | -0.07% |
| Global Health | Equity | 1.74% | -0.17% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 1.71% | +0.04% |
| Healthcare Global Enterprises | Equity | 1.70% | +0.43% |
| Krishna Institute of Medical Sciences | Equity | 1.69% | -0.04% |
| Cohance Lifesciences | Pharmaceuticals & Biotechnology | 1.66% | -0.07% |
| Innova Captab | Pharmaceuticals & Biotechnology | 1.65% | — |
| Dr. Lal Path Labs | Equity | 1.62% | +0.15% |
| Nephrocare Health Services | Equity | 1.12% | -0.06% |
| Syngene International | Equity | 1.12% | -0.12% |
| Rainbow Childrens Medicare | Equity | 0.67% | -0.06% |
| Gufic BioSciences | Pharmaceuticals & Biotechnology | 0.29% | +0.00% |
| Abbott | Pharmaceuticals & Biotechnology | 0.23% | -0.12% |
| 364T191126 | Money Market | 0.05% | +0.00% |
| Novartis | Pharmaceuticals & Biotechnology | 0.04% | — |
| Net Receivable / Payable | Derivatives | -2.01% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 13.25 | 16.27 | Low Volatility |
| 3Y | 13.10 | 16.10 | Low Volatility |
| 5Y | 13.02 | 15.66 | Low Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.83 | -0.33 | Above Average |
| 3Y | 1.24 | -0.46 | Above Average |
| 5Y | 0.91 | 0.28 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.85% (published 2026-10-27).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.96 | 0.05 | Above Average |
| 3Y | 2.56 | 1.11 | Above Average |
| 5Y | 2.08 | 0.94 | Above Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.96 | 0.96 | None |
| 3Y | 0.87 | 0.96 | Good Risk Adjusted Returns |
| 5Y | 0.88 | 0.94 | Good Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+59.16% | +48.17% | — | +23.57% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+23.60% | +30.61% | — | +29.76% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+21.84% | — | — | +19.69% |
|
ICICI Prudential US Bluechip Equity Fund
Regular Plan · IDCW
|
+20.06% | +19.12% | +12.26% | +15.80% |
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+19.95% | — | — | +10.69% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+19.94% | +20.37% | +8.45% | +8.55% |
|
Mirae Asset Healthcare Fund
Direct Plan · Growth
|
+19.10% | +23.89% | +16.63% | +21.84% |
|
PGIM India Healthcare Fund
Direct Plan · Direct IDCW
|
+18.27% | — | — | +11.09% |
|
WhiteOak Capital Pharma and Healthcare Fund
Regular Plan · Growth Option
|
+17.09% | — | — | +20.29% |
|
quant Healthcare Fund
Direct Plan · Growth Option
|
+17.00% | +21.16% | — | +21.00% |
More From SBI Funds Management Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+19.95% | — | — | +10.69% |
|
SBI Silver ETF
Regular Plan · Growth
|
+17.82% | — | — | +31.22% |
|
SBI Silver ETF Fund of Fund
Direct Plan · Growth
|
+17.50% | — | — | +31.50% |
|
SBI Gold ETF
Regular Plan · Growth
|
+13.12% | +29.42% | +22.46% | +12.52% |
|
SBI US Specific Equity Active FoF
Direct Plan · IDCW
|
+12.78% | +25.79% | +15.21% | +17.11% |
|
SBI GOLD FUND
Direct Plan · IDCW
|
+12.69% | +29.55% | +22.51% | +10.27% |
|
SBI MNC FUND
Direct Plan · Growth
|
+10.22% | +6.95% | +7.23% | +14.25% |
|
SBI Children's Fund - Investment Plan
Direct Plan · Growth
|
+7.83% | +20.37% | +17.44% | +30.82% |
|
SBI CREDIT RISK FUND
Direct Plan · IDCW
|
+7.35% | +8.38% | +7.66% | +5.55% |
|
SBI CHILDREN'S FUND - SAVINGS PLAN
Direct Plan · Growth
|
+7.35% | +10.84% | +9.99% | +11.82% |
About This Scheme
Investment Objective
The investment objective of the Scheme is to provide the investors with the opportunity of long term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. There is no assurance that the investment objective of the Scheme will be achieved.
Stated Asset Allocation
Equities and equity related securities in Healthcare space (including derivatives and foreign securities*) 80%-100% High Other equities and equity related instruments 0%-20% High Units issued by REIT/InVIT^ 0%-10% High Debt instruments (including securitized debt) 0%-20% Medium Money market instruments 0%-20% Low
Fund Managers
Mr. Tanmaya Desai 27-Jun-2011
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.